Camidge DR, Kim HR, Ahn MJ, et al. - In the first interim analysis of the open-label, phase 3 ALTA-1L trial (99 events), superior progression-free survival (PFS) and improved health-related quality of life (QoL) resulted from treatment with brigatinib (a next-generation anaplastic lymphoma kinase [ALK] inhibitor) for patients with advanced ALK inhibitor–naive ALK-positive non–small cell lung cancer (NSCLC) vs crizotinib; the outcomes of the second prespecified interim analysis (150 events) are described here. There were 275 patients randomized 1:1 to brigatinib 180 mg once daily (7-day lead-in at 90 mg once daily) or crizotinib 250 mg twice daily. In terms of blinded independent review committee (BIRC)-assessed PFS, brigatinib demonstrated consistent superiority vs crizotinib, after a median follow-up of 24.9 months for brigatinib (150 PFS events). There were no new safety concerns. Median time to worsening of global health status/QoL scores was delayed with brigatinib vs crizotinib. Overall, brigatinib was concluded to be a promising first-line therapy for ALK-positive NSCLC, as this once-daily ALK inhibitor demonstrated superior efficacy, tolerability, and QoL over crizotinib.